Rethinking Clinical Response and Outcome Assessment in a Biologic Age

Current Oncology Reports

Volumn 17, Issue 6, 2015, Pages

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

BCR pathway inhibitors; Checkpoint inhibitors; Follow up; Immunomodulatory; Lenalidomide; PET CR; Response; Tumor flare

Indexed keywords

B LYMPHOCYTE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IBRUTINIB; IDELALISIB; IPILIMUMAB; LENALIDOMIDE; NIVOLUMAB; PEMBROLIZUMAB; PHOSPHOTRANSFERASE INHIBITOR; RITUXIMAB; THALIDOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

AGE; BIOLOGICAL THERAPY; BONE MARROW; CANCER STAGING; CLINICAL TRIAL (TOPIC); DISEASE COURSE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGING; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPH NODE; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; REVIEW; SOLID TUMOR; TREATMENT INDICATION; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA; MOLECULAR TARGETED THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84929377216     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-015-0452-2     Document Type: Review

References (58)

1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds Meeting. J Clin Oncol. 1989;7:1630–6.
2. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244–53.
3. Grillo-López AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of "normal" lymph node size and correlations with response rates. Ann Oncol. 2000;11:399–408.
4. Paul B. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate for detection of lymphoma. J Nucl Med. 1987;28:288–92.
5. Juweid M, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol. 2005;23:4652–61.
6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
7. Cheson BD, Fisher RI, BarrIngton S, et al. Follow-up of the 11-ICML workshop on lymphoma staging and restaging in the PET era. Haematol Oncol. 2013;31:139. abstract #128.
8. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma - the Lugano Classification. J Clin Oncol. 2014;32:3059–68. These recommendations are an update of the 2007 response criteria for lymphoma. They are the first to include PET-CT for not only response assessment, but also staging for FDG-avid lymphomas. Importantly, they suggest that newer agents with unique mechanisms of action might require flexibility in assessment of response.
9. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. The role of imaging in the staging and response assessment of lymphoma: consensus of the ICML Imaging Working Group. J Clin Oncol. 2014;32:3048–58. An international group of nuclear medicine physicians and lymphoma physicians describe the current, appropriate use of PET-CT in the assessment of patients with lymphoma.
10. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.
11. Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903.
12. Han HS, Escalón MP, Hsiao B, et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20:309–18.
13. Smith SM, Grinblatt DL, Johnson JL, et al. Thalidomide has limited single-agent activity in relapsed or refractory indolen non-Hodgkin's lymphoma: a phase II study of the CALGB. Br J Haematol. 2008;140:313–9.
14. Chanan-Khan A, Miller KC, Musialo L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–9.
15. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–7.
16. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–96.
17. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622–7.
18. Eva HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol. 2010;151:410–2.
19. Corazell G, De Filippi R, Capobianco G, et al. Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol. 2010;85:87–90.
20. Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011;155:457–67.
21. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–7.
22. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group Guidelines. Blood. 2008;111:5446–56.
23. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117:2127–35.
24. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phophatidylinositol 3-kinase p 110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7.
25. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406–13.
26. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. This PI3-K inhibitor in combination with rituximab improved response rate and prolonbed survival compared with rituximab alone in unfir patients with CLL. The drug induces an early lymphocytosis caused by a demargination of lymphocytes which could be confused with progressive disease, although other clinical and loboratory disease features are improving.
27. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with indolent lymphoma. N Engl J Med. 2014;370:1008–18.
28. Kahl BS, Spurgeon SE, Furman RR, et al. Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–405.
29. Wang M, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–15.
30. Byrd JC, Brown JR, O'Brien SM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23. In this randomized trial, ibrutinib outperformed ofatumumab and prolonged survival. However, the drug also induces a lymphocytosis which may be prolonged, and could be confused with progressive disease.
31. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
32. Wodarz D, Garg N, Nomarova NL, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123:4132–5.
33. Furtado M, Wang ML, Munneke B, McGreivy J, Beaupre DM, Rule S. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.13275.
34. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9.
35. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7. In this study, the investigators studied the features of the lymphocytosis associated with ibrutinib therapy. Signaling evaluation showed that while BTK is inhibited, downstream mediators of B-cell receptor (BCR) signaling are activated in the persistent lymphocytes. Importantly, the progression-free survival of the patients with or without this lymphocytosis was similar.
36. Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–9.
37. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical endpoints in chronic lymphocytic leukemia. J Clin Oncol. 2012;30:2820–2. A workshop was held to discuss the flare responses associated with various new agents in the treatment of CLL, including lenalidomide and the BCR-pathway targeting agents. To compensate for this finding, the term partial response with lymphocytosis was suggested to facilitate regulatory approval of such agents.
38. Scahadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015. doi:10.1200/JCO.2014.56.2736.
39. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dise-comparison cohort of a phaes 1 trial. Lancet. 2014;384:1109–17.
40. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. The authors describe patterns of response associated with ipilizumab in patients with solid tumors. Increase in the size of tumor masses and even the appearance of new lesions is often the result of an inflammatory reasponse. A similar paradigm should be developed for lymphomas.
41. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockage with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–9.
42. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 124 (suppl): abstract 291, 2014.
43. Westin JR, Chu F, Zhang M, et al. Safety and efficacy of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77.
44. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005;23:4390–8.
45. Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9:1196–203.
46. Radford JA, Eardley A, Woodman C, et al. Follow up policy after treatment for Hodgkin’s disease: too many clinic visits and routine tests? A review of hospital records. Br Med J. 1997;314:343–6.
47. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol. 2003;14:123–30.
48. Ghielmini M, Vitolo U, Kimby E, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561–76.
49. Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014 Jun;12(6):916–46.
50. Castellucci P, Nanni C, Farsad M, et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun. 2005;26:689–94.
51. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781–7.
52. Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 2014;32:3506–12.
53. Guttikonda R, Herts BR, Dong F, et al. Estimated radiation exposure and cancer risk from CT and PET/CT scans in patients with lymphoma. Eur J Radiol. 2014;83:1011–5.
54. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.
55. Casasnovas R-O, Saverot AL, Berriolo-Riedinger A, et al. The 18F-FDG SUVmax reduction after two cycles of R-CHOP regimen predicts progression free survival of patients with diffuse large B-cell lymphoma. Blood. 2009;114:1145–6. abstract #2931.
56. Kostakoglu L, Schoder H, Johnson JL, et al. Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response that each test alone? Leuk Lymphoma. 2012;53:2143–50.
57. Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IgH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27:1659–65. One technique to help distinguish flare or other immunologic-mediated phenomena confused with progressive disease might be the use of sensitive quantitative assays of minimal residual disease.
58. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073–9.